Resultados de la búsqueda 701-710 of 9422 for monoclonal antibody
* Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects). Assessing ...
... antibody) * Olaparib (a type of PARP inhibitor). A Study To Evaluate The Development Of Patient Derived Xenografts In Patients With Breast Cancer. Rochester ...
For various rare immunobullous diseases, detection of a circulating autoantibody is necessary for accurate diagnosis. As a CLIA requirement, every clinical ...
Also want to find out if kidney tumor treatment leads to an improvement in these immune markers. A Study of Hematopoiesis in Patients with Monoclonal B Cell ...
Page 1.
Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...
The purpose of this study is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD and ...
The purpose of this study is to find out more about certain markers of immune suppression in people with kidney tumors (whether the tumors are benign or ...
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?